Document:

Exhibit 10.1

 

	 	 	 
	 	 
	 	Thomas L. Thimot
	 	Chief Executive Officer 
	 	tomthimot@authid.ai
	 	 
	 	April 25, 2022

 

PRIVATE AND CONFIDENTIAL

Hang Thi Bich Pham

7208 Cielo Azul Pass

Austin, TX 78732

 

Re: Employment Offer

 

Dear Annie:

 

On behalf of the Board of
Directors (“Board”) of Ipsidy Inc. dba authID.ai (the “Company”) I take pleasure in extending you
this offer to join the Company as the Chief Financial Officer reporting to the Chief Executive Officer (“CEO”) of the
Company. This offer is subject to formal approval and resolutions of the Board. As part of your responsibilities, you will be required
to provide services to other subsidiaries and affiliates of the Company (together with the Company, collectively referred to as the (“Group”).

 

Job Description

 

Your job responsibilities
will include the following:

 

		●	Timely and accurate annual and quarterly financial reporting in accordance with Securities & Exchange
Commission (“SEC”) rules and regulations, applicable law and United States Generally Accepted Accounting Principles (“GAAP”);

		●	Management of the Finance Department of the Group and oversight of all financial personnel, accounting
systems, procedures and policies of the Group;

		●	Establishing and maintaining adequate financial controls, sufficient as a minimum to enable your appropriate
certification of the Company’s annual and quarterly reports in accordance with SEC rules;

		●	Managing the treasury functions for the Group, as well as all borrowings, debt facilities and equity fundraising,
subject to the approval of the Board;

		●	Undertaking financial planning for the Group, including preparing annual and other budgets and projections
and managing in compliance with such budgets as may be approved by the Board;

		●	Monthly management reporting and analysis for the CEO and the Board;

		●	Investor relations to the extent reasonably requested by the CEO;

		●	Undertake such other responsibilities and tasks as are usual and customary for the position of CFO, as
well as those responsibilities and tasks reasonably assigned to you from time to time by the CEO.

 

Compensation

 

Your compensation package
shall consist of the following:

 

(a)   Initial
base salary of $275,000 per annum, which will be payable semi-monthly in arrears. Your salary will be reviewed by the Company from time
to time and may thereafter be increased.

 

 

 

Ipsidy Inc. ·
670 Long Beach Boulevard, ·
Long Beach, New York 11561 ·
Tel +1 516 274 8700 ·.
www.authid.ai

 

     

     

    

 

	 	 	Hang Thi Bich Pham 
	 	 Page 2
	 	April 25, 2022

 

(b)   You
will also be eligible for an annual target bonus equal to forty percent (40%) of your base salary (pro-rated for the year 2022 by reference
to your start date) based on achievement of performance milestones, calculated and payable in accordance with the corporate milestones
approved by the Board for the year 2022. For subsequent fiscal years the bonus shall be subject to performance targets to be mutually
agreed between you and the Compensation Committee of the Board (the “Committee”);

 

(c)   At
the outset of your employment you shall receive a signing bonus in the amount of $25,000.00 payable on the first payroll date not less
than 30 days after the date of commencement of your employment, which will be fully refundable to the Company if you leave our employment
voluntarily or are terminated for Cause (as defined in the Executive Retention Agreement) prior to the first anniversary of the commencement
of your employment.

 

(d)   At
the outset of your employment you will be provided with an initial grant of options to purchase 350,000 shares of Common Stock of $0.0001
par value in the Company (“Common Stock”), vesting subject to achievement of performance and service conditions as
set forth in the option grant attached hereto as Exhibit “A”. The exercise price of the options shall be equal to the
closing price of the Common Stock on the date of grant, the Exercise Period shall be 10 years and the other terms of the options shall
be as set forth in the aforementioned option grant.

 

(e)   You
may be eligible for equity incentive grants and cash bonus awards, subject to your continued employment and satisfactory job performance,
which may be made from time to time, by the Board or Committee. Terms and conditions of all your equity incentive grants, will be as determined
by the Board or Committee and in accordance with the terms of the Company’s equity incentive plan in effect at the time of each
such grant.

 

(f)   An
Executive Retention Agreement in the form attached hereto as Exhibit “B”.

 

(g)   All
payments of compensation made under this Agreement shall be subject to deduction of all federal, state, local and other taxes required
to be withheld by applicable law.

 

With respect to additional terms of your employment,
the following will apply:

 

		1.	At Will Employment. Your employment shall start on June 2, 2022 or such other date as may be agreed.
While we look forward to a long and mutually beneficial relationship, your employment will be “at-will” and may be terminated
at any time upon written notice and without prior warning. Further, your participation in any stock option or benefit program are not
to be regarded as assuring you of continuing employment for any particular period of time. Any modification or change in your “at-will”
employment status may only occur by way of a written employment agreement signed by you and authorized by the Chief Executive Officer
(“CEO”).

 

		2.	Location and Travel. You will work remotely at your home office. As part of your duties you will
be required to travel as necessary to perform your duties and responsibilities, including visiting Group’s offices in the locations
where they may exist from time to time and attending Group personnel and team meetings from time to time.

 

     

     

    

 

	 	 	Hang Thi Bich Pham 
	 	 Page 3
	 	April 25, 2022

 

		3.	Working Hours. You will be expected to devote your full time and attention to your employment,
to the extent necessary to carry out your duties hereunder. Because of the nature of your position, and as an exempt employee you will
be required to work outside of usual working hours, where the circumstances and business needs require it. You shall not engage or be
involved in any other business activity without the approval of the CEO.

 

		4.	Paid Time Off. You will be entitled to Paid Time Off in accordance with the provisions of the Company’s
Employee Handbook, which has an unlimited reasonable PTO policy, in addition to all public holidays when the office is closed. Vacation
may be taken upon reasonable prior notice to the CEO. The Company’s Employee Handbook contains further provisions relating to your
entitlement and the taking of Paid Time Off.

 

		5.	Sick & Personal Days. Paid Time Off may be used for sick or personal days. The Company’s
Employee Handbook contains further provisions relating to the taking of sick or personal days.

 

		6.	Benefits. You will be eligible to participate in all employee benefit plans established by the
Company for its employees from time to time. The Company currently offers the benefits that are detailed in the Employee Handbook.

 

		7.	Expense Reimbursement. In accordance with Company policies from time to time, we will reimburse
you for all reasonable and proper travel and business expenses incurred by you in the performance of your duties.

 

		8.	Confidentiality and Assignment of Inventions. As an employee and executive of the Company, you
will have access to certain confidential information of the Company and you may, during the course of your employment, develop certain
information or inventions that will be the property of the Company. To protect the interests of the Company, you will need to sign the
Company’s standard “Employee Invention Assignment and Confidentiality Agreement” in the form attached hereto as Exhibit “C”
as a condition of your employment.

 

		9.	Covenants Not to Compete. During the term of this Agreement and, with respect to paragraphs 9(b)
and (c) only, for the period of six (6) months after the termination of your employment by any member of the Group for any reason whatsoever,
you shall not directly or indirectly:

 

		(a)	be employed, or engaged as an independent contractor, consultant, or in any position where your responsibilities
would require you to directly or indirectly support/work on services and/or products that are in competition with the Group’s businesses
as they exist during your employment -- the Group’s businesses currently consist of its biometric identity verification products
and services;

 

		(b)	whether as an employee, independent contractor, consultant, advisor, or principal, enter into any agreement
which is for the provision of services in competition with any of the Group’s businesses, as they exist during your employment or
on the date of your separation from the Company, with any entity, which is or was a customer of the Group(or was in negotiation to become
a customer of the Group), as of or at any time within six (6) months prior to your separation date, nor cause any such customer to enter
into any such competitive agreement with any third party.

 

     

     

    

 

	 	 	Hang Thi Bich Pham 
	 	 Page 4
	 	April 25, 2022

 

		(c)	whether on your own behalf or on behalf of any other person or entity (i) directly or indirectly solicit
any employee of the Group to discontinue such employment relationship with the Group; or (ii) employ or seek to employ any person who
is or was employed by the Group as of or at any time within six (6) months prior to your separation date.

 

You acknowledge that the restrictions
set forth in this paragraph are reasonable and necessary for the protection of the Group’s legitimate interests, in particular having
regard to the sensitive position which you will hold and the high level of confidential and proprietary information regarding the Group’s
business operations, systems and customers to which you will have access, during the performance of your duties hereunder.

 

		10.	Pre-existing obligations. You hereby warrant and represent that you are not subject to any restrictive
covenant, or other agreement, which would prevent you from accepting this offer or from performing your obligations hereunder. To the
extent that you are subject to confidentiality obligations to a former employer or any third party, you acknowledge and agree that it
is your responsibility to ensure that you comply with such obligations on a continuing basis. You acknowledge that the Company is relying
upon your warranty, representation and acknowledgement in this paragraph in making this offer to you. In the event of any claim against
you or the Group by any third party arising out of a breach of this paragraph, you agree to indemnify and hold the Group (and its directors,
officers and employees) harmless from and against all costs, claims and damages arising from such third party’s claim.

 

		11.	Governing Law & Jurisdiction. This offer and your employment shall be governed by and construed
in accordance with the laws of the State of Texas. You and the Company agree to submit to the exclusive personal jurisdiction of the federal
and state courts located in Georgia, in connection with any dispute or proceedings arising out of or relating to this offer and your employment,
and each of us hereby submits to the exclusive jurisdiction of such courts.

 

		12.	Amendment. No amendment or waiver of any of the provisions hereof shall be effective, unless in
writing and signed by each party.

 

		13.	Other Documents. Your employment is subject to Executive Retention Agreement (in the form annexed
hereto) and the Employment Handbook and terms and conditions (including benefits) applicable generally to employees of the Group, from
time to time in force, which are subject to change, amendment, or deletion in the Company’s sole discretion. As a condition of your
employment you will also be required to enter into certain standard undertakings and consents regarding security, confidentiality and
use of the Group’s facilities and property. As part of our objective of continuous improvement and in order to comply with certain
customer and audit requirements, you will also be required to undergo training at least annually on various matters including data security
and sexual harassment. In accordance with our standard policy this employment offer is subject to our receiving satisfactory references
and civil and criminal background checks, and by signing this letter you hereby consent to our undertaking such reference and background
checks.

 

		14.	Authorization to Work. Please note that because of employer regulations adopted in the Immigration
Reform and Control Act of 1986, within three (3) business days of starting your new position you will need to present documentation demonstrating
that you have authorization to work in the United States.

 

     

     

    

 

	 	 	Hang Thi Bich Pham 
	 	 Page 5
	 	April 25, 2022

 

		15.	Severability. If any provision of this letter or the application thereof is held invalid by a court,
arbitrator or government agency of competent jurisdiction, you agree that such a determination of invalidity shall not affect other provisions
or applications of the letter which can be given effect without the invalid provisions and thus shall remain in full force and effect
or application.

 

If the terms and the conditions
of this letter are acceptable to you, please sign, date and return an original of this letter to us.

 

We look forward to a long
and mutually beneficial relationship.

 

	 	Sincerely,
	 	 	 
	 	Ipsidy Inc. dba authID.ai
	 	 	 
	 	By: 	/s/ Thomas L. Thimot
	 	 	Thomas L. Thimot, CEO

 

	AGREED & ACCEPTED:	 	 
	 	 	 
	/s/ Hang Thi Bich Pham	 	 
	HANG THI BICH PHAM	 	Dated:  April 25, 2022

 

     

     

    

 

EXHIBIT A

 

IPSIDY INC.

NON-STATUTORY STOCK
OPTION AGREEMENT

 

 

 

 

This
Non-Statutory Stock Option Agreement (“Agreement”) is made and entered into as of the date set forth below,
by and between Ipsidy Inc., a Delaware corporation (the “Company”), and the following director, employee or consultant
of the Company (“Optionee”):

 

In consideration of the covenants
herein set forth, the parties hereto agree as follows:

 

	 	1.	Option Information.	 
	 	 	(a)	Date of Option:	 
	 	 	(b)	Optionee:	Hang Thi Bich Pham
	 	 	(c)	Number of Shares:	350,000
	 	 	(d)	Exercise Price:	$
	 	 	(e)	Expiration Date:	 
	 	 	(f)	Vesting:	See Section 5

 

		2.	Acknowledgements.

		(a)	Optionee is an Employee of the Company.

 

(b)   The
Board of Directors (the “Board” which term shall include an authorized committee of the Board of Directors) and shareholders
of the Company have heretofore adopted a 2021 Equity Incentive Plan (the “Plan”), pursuant to which this Option is being
granted and which Plan is registered under the Securities Act of 1933, as amended (the “Securities Act”); and

 

(c)   The
Board has authorized the granting to Optionee of a non-statutory stock option (“Option”) to purchase shares of common
stock of the Company (“Stock”) upon the terms and conditions hereinafter stated.

 

3.   Shares;
Price. Company hereby grants to Optionee the right to purchase, upon and subject to the terms and conditions herein stated, the number
of shares of Stock set forth in Section 1(c) above (the “Shares”) for cash, pursuant to a Cashless Exercise as set forth
in Section 6(b), or for other consideration as is authorized under the Plan and acceptable to the Board, in its sole and absolute discretion)
at the price per Share set forth in Section 1(d) above (the “Exercise Price”), such price being not less than the fair
market value per share of the Shares covered by this Option as of the date hereof.

 

4.   Term
of Option; Continuation of Service. This Option shall expire, and all rights hereunder to purchase the Shares shall terminate, ten
(10) years from the date hereof, as set forth in Section 1(e) above (“Expiration Date”). This Option shall earlier
terminate subject to Sections 7 and 8 hereof upon and as of the date of, the termination of Optionee’s office or employment if such termination
occurs prior to the Expiration Date. Nothing contained herein shall confer upon Optionee the right to the continuation of their office
or employment with the Company or to interfere with the right of the Company to terminate such office or employment or to increase or
decrease the compensation of Optionee from the rate in existence at the date hereof.

 

    1

     

    

 

5.   Vesting
of Option. Subject to the provisions of Sections 7 and 8 hereof, this Option shall become exercisable and the Shares shall vest during
the term of Optionee’s office or employment as follows:

 

		(a)	58,333 of the Shares shall vest and become exercisable upon satisfaction of the first to occur of the
following conditions:

 

		(i)	A minimum annualized revenue run-rate of the Company and its subsidiaries on a consolidated basis of $10,000,000,
based on the revenue for any two successive quarterly periods, excluding non-recurring one-time payments (as defined below), determined
in accordance with United States Generally Accepted Accounting Principles (“GAAP”) as shown in any of the Company’s
Annual Reports on Form 10-K, or Quarterly Reports on Form 10-Q filed with the SEC (collectively “SEC Filings”) after
the date hereof; or

 

		(ii)	The Company’s Shares achieving a price on the principal market or exchange on which such shares
are traded, which gives rise to a Fully Diluted Market Capitalization (as defined below) of the Company of not less than $250,000,000
for a period of not less than six consecutive months.

 

		(b)	58,333 of the Shares shall vest and become exercisable upon satisfaction of the first to occur of the
following conditions:

 

		(i)	A minimum annualized revenue run-rate of the Company and its subsidiaries on a consolidated basis of $17,500,000,
based on the revenue for any two successive quarterly periods, excluding non-recurring one-time payments, determined in accordance with
GAAP as shown in any of the Company’s SEC Filings after the date hereof; or

 

		(ii)	The Company’s Shares achieving a price on the principal market or exchange on which such shares
are traded, which gives rise to a Fully Diluted Market Capitalization (as defined below) of the Company of not less than $400,000,000
for a period of not less than six consecutive months.

 

		(c)	58,334 of the Shares shall vest and become exercisable upon satisfaction of the first to occur of the
following conditions:

 

		(i)	A minimum annualized revenue run-rate of the Company and its subsidiaries on a consolidated basis of $25,000,000,
based on the revenue for any two successive quarterly periods, excluding non-recurring one-time payments, determined in accordance with
GAAP as shown in any of the Company’s SEC Filings after the date hereof; or

 

		(ii)	The Company’s Shares achieving a price on the principal market or exchange on which such shares
are traded, which gives rise to a Fully Diluted Market Capitalization (as defined below) of the Company of not less than $475,000,000
for a period of not less than six consecutive months.

 

		(d)	175,000 of the Shares shall vest and become exercisable as to 3,645 of the Shares covered by this Option
at the end of each month commencing with the month following the date of this Option, over a period of forty-seven (47) months, plus a
final instalment of 3,685 Shares, subject to Optionee’s continued service to the Company.

 

    2

     

    

 

		(e)	Upon the occurrence of a Change of Control (as defined below), prior to the occurrence of any of the other
vesting conditions, 100% of the Shares subject to this Option shall vest to the extent not previously vested.

 

		(f)	“Fully Diluted Market Capitalization” shall mean the amount which results from the following calculations or determinations:

 

		(i)	the VWAP of the Shares during the 30 Trading Days immediately prior to each date on which the Fully Diluted
Market Capitalization is to be determined multiplied by

 

		(ii)	the aggregate of the following amounts (1) the number of issued and outstanding Shares of common stock
on the relevant date; and (2) the number of Shares which are issuable pursuant to the exercise of any options of warrants or other instruments
giving the right to call for the issuance of Shares, at an exercise price which is not more than the applicable VWAP under sub-section
(i) above; and (3) the number of Shares which are issuable pursuant to the conversion of any convertible note or other instruments giving
the right to convert into Shares, at a conversion price which is not more than the applicable VWAP under sub-section (i) above.

 

		(d)	“Change of Control” shall have the meaning set forth in Optionee’s Executive
Retention Agreement, except if any of the events set forth in such Agreement occurs in circumstances of the liquidation of the Company
pursuant to a bankruptcy, or other insolvency proceeding.

 

		(e)	“Non-recurring one-time payments”
shall mean any revenue or accounts receivable derived from (i) sales of inventory, goods, equipment,
or other assets of the Group not in the ordinary course of business, (ii) transaction revenue not received in the ordinary course of business,
(iii) sales of services not in the ordinary course of business, or (iv) revenue received due to one-time, non-recurring transactions.

By
way of example, if in a particular quarter the Company has $3,000,000 of revenue but $1,000,000 results from the sale of a subsidiary,
or its assets, then for the purposes of the revenue condition the Company shall be deemed to have had revenue of $2,000,000 in that quarter
and an annualized revenue run rate of $8,000,000.

 

		(f)	“Trading Day” means a day on which the principal trading market for the Shares is open
for trading.

 

		(g)	“VWAP” shall mean, for Shares as of any date,
the dollar volume-weighted average price for such security on the principal market or exchange on which the Shares are traded during each
Trading Day as reported by Nasdaq.

 

		(h)	The installments shall be cumulative (i.e., this option may be exercised, as to any or all Shares covered
by an installment, at any time or times after an installment becomes exercisable and until expiration or termination of this Option).
If any vesting condition is not satisfied before the earlier of the expiration or termination date of this Option, or termination of the
Optionee’s service to the Company, the Option shall lapse as to the unvested Shares.

 

    3

     

    

 

 6. Exercise.

 

(a)   Standard
Exercise. This Option shall be exercised by delivery to the Company of (i) written notice of exercise stating the number of Shares
being purchased (in whole shares only) and such other information set forth on the form of Notice of Exercise attached hereto as Appendix
A; and (ii) a check or wire transfer in the amount of the Exercise Price of the Shares covered by the notice (or such other consideration
as has been approved by the Board consistent with the Plan) and any taxes (including withholding taxes) payable by the Optionee upon exercise.
This Option shall not be assignable or transferable, except by will or by the laws of descent and distribution, and shall be exercisable
only by Optionee during their lifetime, except as provided in Section 8 hereof.

 

(b)   Cashless
Exercise. Notwithstanding anything to the contrary contained in this Option, this Option may be exercised by presentation and surrender
of this Option to the Company at its principal executive offices with (i) a written notice of the holder’s intention to effect a
cashless exercise, and such other information set forth on the form of Notice of Exercise attached hereto as Appendix A, (a “Cashless
Exercise”); and (ii) a check or wire transfer in the amount of any taxes (including withholding taxes) payable by the Optionee
upon exercise. In the event of a Cashless Exercise, in lieu of paying the Exercise Price in cash, the holder shall surrender this Option
for that number of shares of Common Stock determined by multiplying the number of Shares to which it would otherwise be entitled by a
fraction, the numerator of which shall be the difference between the then current Market Price per share of the Common Stock and the Exercise
Price, and the denominator of which shall be the then current Market Price per share of Common Stock. Market Price is defined as the average
of the last reported sale prices on the principal trading market for the Common Stock during the five (5) trading days immediately preceding
such exercise date. Market Price and the number of Shares issuable on a Cashless Exercise shall be as calculated by the Company, whose
determination thereof shall be final save in the case of mathematical or other manifest error.

 

Further, if implemented by the Company,
all or part of the Exercise Price and any taxes (including withholding taxes) may be paid by the delivery (on a form prescribed by the
Company) of an irrevocable direction to a securities broker approved by the Company to sell Shares and to deliver all or part of the sales
proceeds to the Company.

 

7.   Termination
of Employment.

 

(a)   If
Optionee shall cease to be a director, employee or contractor of the Company for any reason, whether voluntarily or involuntarily, other
than by their death, Optionee (or if the Optionee shall die after such termination, but prior to such exercise date, Optionee’s personal
representative or the person entitled to succeed to the Option) shall have the right at any time within three (3) months following such
termination of office or the remaining term of this Option, whichever is the lesser, to exercise in whole or in part this Option to the
extent, but only to the extent, that this Option was exercisable as of the date of termination of office and had not previously been exercised;
provided, however: (i) if Optionee is permanently disabled (within the meaning of Section 22(e)(3) of the Code) at the time of termination,
the foregoing three (3) month period shall be extended to one (1) year; or (ii) if Optionee is terminated for “Cause”
(as defined below) this Option shall automatically terminate as to all Shares covered by this Option not exercised prior to termination.
Unless earlier terminated, all rights under this Option shall terminate in any event on the Expiration Date.

 

(b)   If
the term “Cause” is defined in any employment agreement between the Optionee and the Company, then such definition shall
be used. In all other cases “Cause” in this Agreement means (i) an intentional
act of fraud, embezzlement, theft or any other material violation of law that occurs during or in the course of Optionee’s employment
or office with Company; (ii) intentional damage to the Company’s assets; (iii) intentional disclosure of Company’s confidential
information contrary to the Company’s policies; (iv) breach of Optionee’s obligations to the Company; (v) intentional engagement
in any competitive activity which would constitute a breach of Optionee’s duty of loyalty or of Optionee’s obligations to
the Company; (vi) intentional breach of any of Company’s policies; (vii) the willful and continued failure to substantially perform
Optionee’s duties for Company (other than as a result of incapacity due to physical or mental illness); or (viii) willful conduct
by Optionee that is demonstrably and materially injurious to the Company, monetarily or otherwise.

 

    4

     

    

 

8.   Death
of Optionee. If the Optionee shall die while holding office of the Company, Optionee’s personal representative or the person entitled
to Optionee’s rights hereunder may at any time within one (1) year after the date of Optionee’s death, or during the remaining term of
this Option, whichever is the lesser, exercise this Option and purchase Shares to the extent, but only to the extent, that Optionee could
have exercised this Option as of the date of Optionee’s death; provided, in any case, that this Option may be so exercised only to the
extent that this Option has not previously been exercised by Optionee.

 

9.   No
Rights as Shareholder. Optionee shall have no rights as a shareholder with respect to the Shares covered by any installment of this
Option until the effective date of issuance of the Shares following exercise of this Option, and no adjustment will be made for dividends
or other rights for which the record date is prior to the date such Shares are issued except as provided in Section 10 hereof.

 

10.   Recapitalization.
Subject to any required action by the shareholders of the Company, the number of Shares covered by this Option, and the Exercise Price
thereof, shall be proportionately adjusted for any increase or decrease in the number of issued shares resulting from a subdivision or
consolidation of shares or the payment of a stock dividend, or any other increase or decrease in the number of such shares effected without
receipt of consideration by the Company; provided however that the conversion of any convertible securities of the Company shall not be
deemed having been “effected without receipt of consideration by the Company”.

 

11.   Reorganization.
The grant of this Option shall not affect in any way the right or power of the Company to make adjustments, reclassifications, reorganizations
or changes in its capital or business structure or to merge, consolidate, dissolve or liquidate or to sell or transfer all or any part
of its business or assets. The provisions of the Plan shall govern the rights of the Optionee in the event of a Reorganization as defined
in the Plan.

 

12.   Taxation
upon Exercise of Option. Optionee understands that, upon exercise of this Option, Optionee will recognize income, for Federal and
state income tax purposes, in an amount equal to the amount by which the fair market value of the Shares, determined as of the date of
exercise, exceeds the Exercise Price. The acceptance of the Shares by Optionee shall constitute an agreement by Optionee to report such
income in accordance with then applicable law and to cooperate with Company in establishing the amount of such income and corresponding
deduction to the Company for its income tax purposes. Withholding for federal or state income and employment tax purposes will be made,
if and as required by law, from Optionee’s then current compensation, or, if such current compensation is insufficient to satisfy withholding
tax liability, the Company may require Optionee to make a cash payment to cover such liability as a condition of the exercise of this
Option.

 

13.   Modification,
Extension and Renewal of Options. The Board or Committee, as described in the Plan, may modify, extend or renew this Option or accept
the surrender thereof (to the extent not theretofore exercised) and authorize the granting of a new option in substitution therefore (to
the extent not theretofore exercised), subject at all times to the Plan, the Code and all relevant securities statutes and rules. Notwithstanding
the foregoing provisions of this Section 13, no modification shall, without the consent of the Optionee, alter to the Optionee’s detriment
or impair any rights of Optionee hereunder.

 

    5

     

    

 

14.   Stand-off
Agreement. Optionee agrees that, in connection with any registration of the Company’s securities under the Securities Act, and upon
the request of the Company or any underwriter managing an underwritten offering of the Company’s securities, Optionee shall not sell,
short any sale of, loan, grant an option for, or otherwise dispose of any of the Shares (other than Shares included in the offering) without
the prior written consent of the Company or such managing underwriter, as applicable, for a period of at least six months following the
effective date of registration of such offering.

 

15.   Notices.
Any notice required to be given pursuant to this Option or the Plan shall be in writing and delivered to the Company Attn: General Counsel
and shall be deemed to be delivered upon receipt, or by e-mail to legal@authid.ai, or in the case of notices by the Company, five (5)
days after deposit in the U.S. mail, postage prepaid, or by e-mail addressed to Optionee at the address last provided by Optionee for
their employee/officer records.

 

16.   Agreement
Subject to Plan; Applicable Law. This Option is made pursuant to the Plan and shall be interpreted to comply therewith. A copy of
such Plan is available to Optionee, at no charge, at the principal office of the Company. Any provision of this Option inconsistent with
the Plan shall be considered void and replaced with the applicable provision of the Plan, except to the extent expressly approved by the
Board. This Option has been granted, executed and delivered in the State of Delaware, and the interpretation and enforcement shall be
governed by the laws thereof and subject to the exclusive jurisdiction of the courts therein.

 

17.   Data
Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company,
its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and
all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone
number, date of birth and other information that is necessary or desirable for the administration of the Plan or this Agreement (the “Relevant
Information”). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer
to the Relevant Companies all Relevant Information; (ii) authorizes the Relevant Companies to store and transmit such information in electronic
form; and (iii) authorizes the transfer of the Relevant Information to any jurisdiction which the Relevant Companies consider appropriate.
The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be processed and
used in accordance with applicable law and in accordance with the Company’s privacy policy from time to time in force.

 

[Signature page follows]

 

    6

     

    

 

In
Witness Whereof, the parties hereto have executed this Option Agreement as of the date first above written.

 

	 	COMPANY: 	Ipsidy Inc.,
	 	 	a Delaware corporation
	 	 	 	 
	 	 	By:	 
	 	 	Name:  	 Thomas L. Thimot
	 	 	Title:   CEO
	 	 	 	 
	 	OPTIONEE:	 	 
	 	 	 	 
	 	 	By: 	 
	 	 	 	(signature)
	 	 	Name:	HANG THI BICH PHAM

 

    7

     

    

 

Appendix A

 

NOTICE OF EXERCISE

Ipsidy Inc.

________________

________________

 

Re: Non-statutory Stock
Option

 

Notice is hereby given pursuant
to Section 6 of my Non-statutory Stock Option Agreement that I elect to purchase the number of shares set forth below at the exercise
price set forth in my option agreement:

 

Non-statutory Stock Option
Agreement dated: ____________

 

Number of shares being purchased:
____________

 

Exercise Price: $____________

 

EITHER

 

1)   A
check in the amount of the aggregate price of the shares being purchased is attached/wire transfer for such amount is being sent.

 

OR

 

2)   I
elect a cashless exercise pursuant to Section 6 of my Stock Option Agreement.

The Company shall determine the Market Price*
as of the date of this Exercise Notice and the resulting number of shares of common stock to be issued on a cashless exercise basis and
promptly notify the Option holder thereof.

 

* Market Price is defined as the average of the
last reported sale prices on the principal trading market for the Common Stock during the five (5) trading days immediately preceding
such exercise date.

 

Further, I understand that
the exercise of the Options will give rise to taxable income at the time of exercise, and that taxes will be payable in addition to the
Exercise Price under the Option, whether by deduction from my compensation, or by my additional payment to the Company.

 

I agree to provide to the
Company such additional documents or information as may be required pursuant to the Company’s 2021 Equity Incentive Plan.

 

By: ______________________

 

Dated: ____________________

 

     

     

    

 

EXHIBIT B

 

EXECUTIVE RETENTION AGREEMENT

 

This Executive Retention Agreement
(the “Agreement”) is made and entered into as of April 25, 2022 by and between IPSIDY INC., a Delaware corporation
(the “Company”), and HANG THI BICH PHAM (the “Executive”).

 

Recitals:

 

WHEREAS, the Executive is
a key employee of the Company who possesses valuable proprietary knowledge of the Company, its business and operations and the markets
in which the Company competes; and

 

WHEREAS, the Company and the
Executive desire to enter into this Agreement to encourage the Executive to continue to devote the Executive’s full attention and
dedication to the success of the Company, and to provide specified compensation and benefits to the Executive in the event of a Termination
Upon Change of Control or certain other terminations pursuant to the terms of this Agreement.

 

NOW, THEREFORE, THE PARTIES HEREBY AGREE AS FOLLOWS:

1.   PURPOSE
AND TERM

 

The purpose of this Agreement
is to provide specified compensation and benefits to the Executive in the event of (i) a Termination Upon Change of Control or (ii) an
Involuntary Termination. Subject to the terms of any applicable written employment agreement between Company and the Executive (as to
which Executive acknowledges no other such agreement exists as of the date hereof), either the Executive or Company may terminate the
Executive’s employment at any time for any reason, with or without notice. The term of this Agreement shall be the period from the
date set forth above until Executive’s employment is terminated for any reason or this Agreement is terminated by mutual agreement
of the parties.

 

2.   TERMINATION
GENERALLY

 

2.1   Termination
of Employment Generally. In the event the Executive’s employment with the Company terminates, for any reason whatsoever including
death or disability the Executive shall be entitled to the benefits described in this Section 2.1.

 

2.1.1   Accrued
Salary and Vacation. All salary and accrued vacation earned through the Termination Date shall be paid to Executive on such Date.

 

2.1.2   Accrued
Bonus Payment. The Executive shall receive a lump sum payment of any actual bonus amount to the extent that all the conditions for
payment of such bonus have been satisfied and any such bonus was earned and is unpaid on the Termination Date.

 

2.1.3   Expense
Reimbursement. Within ten (10) days following submission to the Company of proper expense reports by the Executive, the Company shall
reimburse the Executive for all expenses incurred by the Executive, consistent with the Company’s expense reimbursement policy in
effect prior to the incurring of each such expense, in connection with the business of the Company prior to the Termination Date.

 

     

     

    

 

3.   TERMINATION
UPON CHANGE OF CONTROL

 

3.1   Severance
Payment. In the event of the Executive’s Termination Upon Change of Control, the Executive shall be entitled to receive an amount
equal to twelve (12) months of the Executive’s Base Salary and 100% of Executive’s target annual bonus for the year in which
the Termination Date occurs (or, if greater, the target annual bonus in effect immediately prior to the Change of Control) which shall
be paid in a lump sum payment within ten (10) days following the Termination Date; provided, however, that if Section 409A of the Code
would otherwise apply to such cash severance payment, it instead shall be paid at such time as permitted by Section 409A of the Code.
The severance payment payable hereunder shall be reduced to the extent of the amount of any bonus payable to Executive upon a Change of
Control.

 

3.2   COBRA.
The Company will reimburse Executive for the cost of continuation of health coverage for Executive and Executive’s eligible dependents
pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) until the earlier
of (i) 12 months following the Termination Date, (ii) the date Executive is eligible for health coverage for Executive and Executive’s
eligible dependents from a new employer or (iii) the date Executive and Executive’s eligible dependents are no longer eligible for
COBRA; provided, however, if, at the time of the Termination Date, the Company determines that providing the COBRA reimbursement in this
paragraph would result in a violation of law or an excise tax to the Company, then the Company instead will pay a lump sum payment equal
to 150% of 12 months of Executive’s estimated COBRA premiums, less applicable withholdings, within 10 days following the Termination
Date.

 

3.3   Equity
Compensation Acceleration. Upon the Executive’s Termination Upon Change of Control, the vesting and exercisability of all then
outstanding stock options and shares of restricted stock (or any other equity award, including, without limitation, stock appreciation
rights and restricted stock units) granted to the Executive under any Company Plans shall be accelerated as to 100% of the shares subject
to any such equity awards granted to the Executive.

 

3.4   Indemnification.
In the event of the Executive’s Termination Upon Change of Control, (a) the Company shall continue to indemnify the Executive against
all claims related to actions arising prior to the termination of the Executive’s employment to the fullest extent permitted by
law, and (b) if the Executive was covered by the Company’s directors’ and officers’ insurance policy, or an equivalent
thereto, (the “D&O Insurance Policy”) immediately prior to the Change of Control, the Company or its Successor
shall continue to provide coverage under a D&O Insurance Policy for not less than twenty-four (24) months following the Executive’s
Termination Upon Change of Control on substantially the same terms of the D&O Insurance Policy in effect immediately prior to the
Change of Control.

 

4.   INVOLUNTARY
TERMINATION

 

4.1   Severance
Payment. In the event of the Executive’s Involuntary Termination, the Executive shall be entitled to receive an amount equal
to twelve (12) months of the Executive’s Base Salary, which shall be paid according to the following schedule: (i) a lump sum payment
equal to one-fourth of such amount shall be payable within ten (10) days following the Termination Date, and (ii) one-fourth of such amount
shall be payable within ten (10) days of each of the three-month, six-month and nine-month anniversaries of the Termination Date (and
in each case no interest shall accrue on such amount); provided, however, that if Section 409A of the Code would otherwise apply to such
cash severance payment, it instead shall be paid at such time as permitted by Section 409A of the Code. Notwithstanding the foregoing,
if the Involuntary Termination occurs within the first twelve (12) months following the Effective Date, the amounts paid will instead
equal six (6) months of the Executive’s Base Salary.

 

    2

     

    

 

 

4.2 Bonus
Payment. In addition to the foregoing severance payment, in the event of the Executive’s Involuntary Termination, the Executive
shall be entitled to receive, within ten (10) days following the Executive’s Involuntary Termination, a lump sum payment equal to
one hundred percent (100%) of (a) any actual bonus amount earned with respect to a previous year to the extent that all the conditions
for payment of such bonus have been satisfied (excluding any requirement to be in employment with the Company as of a given date which
is after the Termination Date) and any such bonus was earned but is unpaid on the Termination Date; and (b) the target bonus then in effect
for the Executive for the year in which such termination occurs, such payment to be prorated to reflect the full number of months the
Executive remained in the employ of the Company (the majority of a month counting as a full month); provided, however, that if Section
409A of the Code would otherwise apply to such cash payment, it instead shall be paid at such time as permitted by Section 409A of the
Code. To illustrate, if the Executive’s target bonus at 100% equals $120,000 for the calendar year and the Executive is terminated
on October 16th, then the foregoing payment shall equal $100,000 (i.e., ten (10) months’ prorated bonus at one hundred
percent (100%) with October counting as a full month worked).

 

4.3 COBRA.
The Company will reimburse Executive for the cost of continuation of health coverage for Executive and Executive’s eligible dependents
pursuant to COBRA until the earlier of (i) 12 months following the Termination Date, (ii) the date Executive is eligible for health
coverage for Executive and Executive’s eligible dependents from a new employer or (iii) the date Executive and Executive’s
eligible dependents are no longer eligible for COBRA; provided, however, if, at the time of the Termination Date, the Company determines
that providing the COBRA reimbursement in this paragraph would result in a violation of law or an excise tax to the Company, then the
Company instead will pay a lump sum payment equal to 150% of 12 months of Executive’s estimated COBRA premiums, less applicable
withholdings, within 10 days following the Termination Date.

 

4.4 Equity
Compensation Exercise. Upon the Executive’s Involuntary Termination, (i) the Exercise Period with respect to vested Shares,
under the Company Plans for the purposes of the Executive’s stock options granted under the Company Plans shall be extended so as
to expire two (2) years from the date of Involuntary Termination or the remaining term of the relevant equity award, whichever is the
lesser; and (ii) the vesting and exercisability of then outstanding stock options and shares of restricted stock (or any other equity
award, including, without limitation, stock appreciation rights and restricted stock units) granted to the Executive under any Company
Plans shall be accelerated as to such number of the shares subject to any such equity awards granted to the Executive, as would (but for
such Termination) vest during the period of 12 months following the date of Involuntary Termination. All other unvested Shares under any
such grants or other equity awards shall lapse and no longer be exercisable as of the date of Involuntary Termination.

 

4.5 Indemnification.
In the event of the Executive’s Involuntary Termination, (a) the Company shall continue to indemnify the Executive against all claims
related to actions arising prior to the Termination Date to the fullest extent permitted by law, and (b) if the Executive was covered
by the D&O Insurance Policy immediately prior to the Termination Date, the Company shall continue to provide coverage under a D&O
Insurance Policy for not less than twenty-four (24) months following the Executive’s Involuntary Termination on substantially the
same terms of the D&O Insurance Policy in effect immediately prior to the Termination Date.

 

    3

     

    

 

5. FEDERAL
EXCISE TAX UNDER SECTION 280G

 

5.1 Excise
Tax. If (a) any amounts payable to the Executive under this Agreement or otherwise are characterized as excess parachute payments
pursuant to Section 4999 of the Internal Revenue Code of 1986, as amended (the “Code”), and (b) the Executive
thereby would be subject to any United States federal excise tax due to that characterization, then such amounts will either be (i) delivered
in full, or (ii) delivered to such lesser extent which would result in no portion of such amounts being subject to excise tax pursuant
to Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes
and the excise tax imposed by Code Section 4999, results in Executive’s receipt on an after-tax basis, of the greatest amounts,
notwithstanding that all or some portion of such amounts may be taxable under Code Section 4999. If a reduction in the amounts constituting
“parachute payments” is necessary so that no portion of such amounts are subject to the excise tax under Code Section 4999,
the reduction will occur in the following order: (i) reduction of the cash severance payments, which will occur in reverse chronological
order such that the cash payment owed on the latest date following the occurrence of the event triggering such excise tax will be the
first cash payment to be reduce; (ii) cancellation of accelerated vesting of equity awards which will occur in the reverse order of the
date of grant for such stock awards (i.e., the vesting of the most recently granted stock awards will be reduced first); and (iii) reduction
of continued employee benefits, which will occur in reverse chronological order such that the benefit owed on the latest date following
the occurrence of the event triggering such excise tax will be the first benefit to be reduced. If two or more equity awards are granted
on the same date, each award will be reduced on a pro-rata basis. Notwithstanding the foregoing, no such reduction or elimination shall
apply to any non-qualified deferred compensation amounts (within the meaning of Section 409A of the Code) to the extent such reduction
or elimination would accelerate or defer the timing of such payment in a manner that does not comply with Section 409A of the Code.

 

5.2 Calculation
by Independent Public Accountants. Unless the Company and the Executive otherwise agree in writing, any calculation of the amount
of any excess parachute payments payable by the Executive shall be made in writing by the Company’s independent public accountants
(the “Accountants”) whose conclusion shall be final and binding on the parties. For purposes of making such
calculations, the Accountants may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999
of the Code. The Company and the Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably
request in order to make the required calculations. The Company shall bear all fees and expenses the Accountants may charge in connection
with these services, but the engagement of the Accountants for this purpose shall be pursuant to an agreement between the Executive and
the Accountants.

 

6. DEFINITIONS

 

6.1 Capitalized
Terms Defined. Capitalized terms used in this Agreement shall have the meanings set forth in this Section 4, unless the context clearly
requires a different meaning.

 

6.2 “Base
Salary” means the greater of (a) if applicable, the monthly salary of the Executive in effect immediately prior to the Change
of Control, or (b) the monthly salary of the Executive in effect immediately prior to the Termination Date.

 

6.3 “Cause”
means:

 

		(a)	the Executive willfully failed to follow the lawful written directions of
the Board of Directors of the Company (the “Board”) or Executive’s immediate superior; provided that no
termination for such Cause shall occur unless the Executive: (i) has been provided with notice, specifying such willful failure in reasonable
detail, of the Company’s intention to terminate the Executive for Cause; and (ii) has failed to cure or correct such willful failure
within thirty (30) days of receiving such notice; 

 

    4

     

    

 

		(b)	the Executive engaged in gross misconduct, or gross incompetence which is
materially detrimental to the Company; provided that no termination for such Cause shall occur unless the Executive: (i) has been provided
with notice, specifying such gross misconduct or gross incompetence in reasonable detail, of the Company’s intention to terminate
the Executive for Cause; and (ii) has failed to cure or correct such gross misconduct within thirty (30) days of receiving such notice;

 

		(c)	the Executive willfully failed to comply in any material respect with the
Employee Invention Assignment & Confidentiality Agreement, the Company’s share dealing code, the Executive’s non-competition
agreement, or any other reasonable policies of the Company where non-compliance would be materially detrimental to the Company; provided
that no termination for such Cause shall occur unless the Executive: (i) has been provided with notice of the Company’s intention
to terminate the Executive for such Cause, and (ii) has failed to cure or correct such willful failure within thirty (30) days of receiving
such notice, provided that such notice and cure period requirements shall not apply in the event that such non-compliance is of a nature
that it is unable to be remedied; or

 

		(d)	The Executive is convicted of a felony or crime involving moral turpitude
(excluding drunk driving unless combined with other aggravating circumstances or offenses) or commission of a fraud that the Company reasonably
believes would have a material adverse effect on the Company.

 

6.4 “Change
of Control” means:

 

		(a)	any “person” (as such term is used in Sections 13(d) and 14(d)
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) becomes the “beneficial owner”
(as defined in Rule 13d-3 promulgated under the Exchange Act), directly or indirectly, of securities of the Company representing fifty
(50%) percent or more of (i) the outstanding shares of common stock of the Company, or (ii) the combined voting power of the Company’s
outstanding securities;

 

		(b)	the Company is party to a merger or consolidation, or series of related
transactions, which results in the voting securities of the Company outstanding immediately prior thereto failing to continue to represent
(either by remaining outstanding or by being converted into voting securities of the surviving entity), directly or indirectly, at least
fifty (50%) percent of the combined voting power of the voting securities of the Company or such surviving entity outstanding immediately
after such merger or consolidation;

 

		(c)	the sale or disposition of all or substantially all of the Company’s
assets, or consummation of any transaction, or series of related transactions, having similar effect (other than to a subsidiary of the
Company); 

 

    5

     

    

 

		(d)	a change in the composition of the Board within any consecutive two-year
period, as a result of which fewer than a majority of the directors are Incumbent Directors. “Incumbent Directors” shall mean
directors who either (i) were directors of the Company as of the effective date of this Agreement, or (ii) are elected, or nominated for
election, to the Board with the affirmative votes of a least a majority of those directors whose election or nomination was not in connection
with an actual or threatened proxy contest related to the election of directors to the Company; or

 

		(e)	the dissolution or liquidation of the Company. 

 

6.5 “Company”
shall mean IPSIDY INC. and, following a Change of Control, any Successor.

 

6.6 “Company
Plans” shall mean the Company’s 2021 Equity Incentive Plan and any employee equity plan that replaces or supplements
such plan, as well as any grant of stock options, restricted stock, stock appreciation rights, stock award, or stock purchase offer, which
may be made to Executive outside of any such plan.

 

6.7 “Involuntary
Termination” means:

 

		(a)	any termination without Cause of the employment of the Executive by the
Company; or

 

		(b)	any resignation by Executive for Good Reason where such resignation occurs
within one hundred twenty (120) days following the occurrence of such Good Reason.

 

Notwithstanding the foregoing, the term “Involuntary
Termination” shall not include any termination of the employment of the Executive: (1) by the Company for Cause; (2) by the Company
as a result of the Permanent Disability of the Executive; (3) as a result of the death of the Executive; (4) as a result of the voluntary
termination of employment by the Executive for any reason other than Good Reason, or (5) that would qualify as a Termination Upon Change
of Control hereunder.

 

6.8 “Good
Reason” means the occurrence of any of the following conditions, without the Executive’s written consent:

 

		(a)	Any act, set of facts or omissions with respect to the Executive that would,
as a matter of applicable law, constitute a constructive termination of the Executive.

 

		(b)	The assignment to the Executive of a title, position, responsibilities or
duties that is not a “Substantive Functional Equivalent” to the title, position, responsibilities or duties which the Executive
had immediately prior to such assignment (including, as relevant, immediately prior to the public announcement of the Change of Control).

 

		(c)	A material reduction in the Executive’s Base Salary or, if applicable,
target bonus opportunity (subject to applicable performance requirements with respect to the actual amount of bonus compensation earned
similar to the applicable performance requirements currently in effect), and in the event of a Change of Control, as compared to Executive’s
Base Salary and target bonus opportunity in effect immediately prior to the public announcement of the Change of Control; provided, however,
that this clause (c) shall not apply in the event of a reduction in the Executive’s Base Salary or, if applicable, target bonus
opportunity as part of a Company-wide or executive team-wide cost-cutting measure or Company-wide or executive team-wide cutback as a
result of overall Company performance. 

 

    6

     

    

 

		(d)	The failure of the Company (i) to continue to provide the Executive an opportunity
to participate in any benefit or compensation plans provided to employees who hold positions with the Company comparable to the Executive’s
position, (ii) to provide the Executive all other fringe benefits (or the equivalent) in effect for the benefit of any employee group
which includes any employee who hold a position with the Company comparable to the Executive’s position, where in the event of a
Change of Control, such comparison shall be made relative to the time immediately prior to the public announcement of such Change of Control);
or (iii) continue to provide director’s and officers’ insurance.

 

		(e)	A material breach of this Agreement by the Company, including, in the event
of a Change of Control, failure of the Company to obtain the consent of a Successor to perform all of the obligations of the Company under
this Agreement.

 

The Executive must first give the Company an opportunity
to cure any of the foregoing within thirty (30) days following delivery to the Company of a written explanation specifying the specific
basis for Executive’s belief that Executive is entitled to terminate employment for Good Reason, and Executive terminates employment
with the Company not later than (30) days following the Company’s failure to cure.

 

6.9 “Permanent
Disability” means that:

 

		(a)	the Executive has been incapacitated by bodily injury, illness or disease
so as to be prevented thereby from engaging in the performance of the Executive’s duties;

 

		(b)	such total incapacity shall have continued for a period of six consecutive
months; and

 

		(c)	such incapacity will, in the opinion of a qualified physician, be permanent
and continuous during the remainder of the Executive’s life.

 

6.10 “Substantive
Functional Equivalent” means that the Executive’s position must:

 

		(a)	be in a substantive area of the Executive’s competence (e.g., finance
or executive management) and not materially different from the position occupied immediately prior;

 

		(b)	allow the Executive to serve in a role and perform duties functionally equivalent
to those performed immediately prior; and

 

		(c)	not otherwise constitute a material, adverse change in authority, title,
status, responsibilities or duties from those of the Executive immediately prior, causing the Executive to be of materially lesser rank
or responsibility, including requiring the Executive to report to a person other than the Board.

 

    7

     

    

 

6.11 “Successor”
means any successor in interest to, or assignee of, substantially all of the business and assets of the Company.

 

6.12 “Termination
Date” means the date of the termination of the Executive’s employment with the Company.

 

6.13 “Termination
Upon Change of Control” means:

 

		(a)	any termination of the employment of the Executive by the Company without
Cause during the period commencing on or after the date that the Company first publicly announces a definitive agreement that results
in a Change of Control (even though still subject to approval by the Company’s stockholders and other conditions and contingencies,
but provided that the Change of Control actually occurs) and ending on the date which is twelve (12) months following the Change of Control;
or

 

		(b)	any resignation by Executive for Good Reason where (i) such Good Reason
occurs during the period commencing on or after the date that the Company first publicly announces a definitive agreement that results
in a Change of Control (even though still subject to approval by the Company’s stockholders and other conditions and contingencies,
but provided that the Change of Control actually occurs) and ending on the date which is twelve (12) months following the Change of Control,
and (ii) such resignation occurs at or after such Change in Control and in any event within twelve (12) months following the expiration
of any Company cure period.

 

Notwithstanding the foregoing, the term “Termination
Upon Change of Control” shall not include any termination of the employment of the Executive: (1) by the Company for Cause; (2)
by the Company as a result of the Permanent Disability of the Executive; (3) as a result of the death of the Executive; or (4) as
a result of the voluntary termination of employment by the Executive for any reason other than Good Reason.

 

7. EXCLUSIVE
REMEDY

 

7.1 No
Other Benefits Payable. The Executive shall be entitled to no other termination, severance or change of control compensation, benefits,
or other payments from the Company as a result of any termination with respect to which the payments and benefits described in Section
2 have been provided to the Executive, except as expressly set forth in this Agreement.

 

7.2 No
Limitation of Regular Benefit Plans. Except as may be provided elsewhere in this Agreement, this Agreement is not intended to and
shall not affect, limit or terminate any plans, programs or arrangements of the Company that are regularly made available to a significant
number of employees or officers of the Company, including, without limitation, the Company’s stock option plans.

 

7.3 Release
of Claims. The payment of the benefits described in Sections 3 and 4 of this Agreement is conditioned upon the delivery by the Executive
to the Company of a signed and effective general release of claims as provided by the Company in the form attached hereto as Exhibit 1;
provided, however, that the Executive shall not be required to release any rights the Executive may have to be indemnified by the Company
or as otherwise provided under this Agreement.

 

7.4 Noncumulation
of Benefits. The Executive may not cumulate cash severance payments, stock option vesting and exercisability and restricted stock
vesting under this Agreement, any other written agreement with the Company and/or another plan or policy of the Company. If the Executive
has any other binding written agreement with the Company which provides that, upon a Change of Control or Termination Upon a Change of
Control or Involuntary Termination, the Executive shall receive termination, severance or similar benefits, then no benefits shall be
received by Executive under this Agreement unless, prior to payment or receipt of benefits under this Agreement, the Executive waives
Executive’s rights to all such other benefits, in which case this Agreement shall supersede any such written agreement with respect
to such other benefits.

 

    8

     

    

 

8. ARBITRATION

 

8.1 Disputes
Subject to Arbitration. Any claim, dispute or controversy arising out of this Agreement (other than claims relating to misuse or misappropriation
of the intellectual property of the Company), the interpretation, validity or enforceability of this Agreement or the alleged breach thereof
shall be submitted by the parties to binding arbitration by a sole arbitrator under the rules of the American Arbitration Association;
provided, however, that (a) the arbitrator shall have no authority to make any ruling or judgment that would confer any rights with respect
to the trade secrets, confidential and proprietary information or other intellectual property of the Company upon the Executive or any
third party; and (b) this arbitration provision shall not preclude the Company from seeking legal and equitable relief from any court
having jurisdiction with respect to any disputes or claims relating to or arising out of the misuse or misappropriation of the Company’s
intellectual property. Judgment may be entered on the award of the arbitrator in any court having jurisdiction.

 

8.2 Costs
of Arbitration. All costs of arbitration, including reasonable attorney’s fees of the Executive, will be borne by the Company,
except that if the Executive initiates arbitration and the arbitrator finds the Executive’s claims to be frivolous the Executive
shall be responsible for their own costs and attorneys’ fees.

 

8.3 Site
of Arbitration. The site of the arbitration proceeding shall be in Austin, Texas.

 

9. NOTICES

 

For purposes of this Agreement, notices and all
other communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered or five
(5) business days after being mailed, return receipt requested, as follows: (a) if to the Company, attention: General Counsel, at the
Company’s offices at 670 Long Beach Boulevard, Long Beach, New York 11561 USA or legal@ipsidy.com and, (b) if to the Executive,
at the address indicated below or such other address specified by the Executive in writing to the Company. Either party may provide the
other with notices of change of address, which shall be effective upon receipt.

 

12. MISCELLANEOUS PROVISIONS

 

12.1 Heirs
and Representatives of the Executive; Successors and Assigns of the Company. This Agreement shall be binding upon and shall inure
to the benefit of and be enforceable by the Executive’s personal and legal representatives, executors, administrators, successors,
heirs, distributees, devises and legatees. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the
successors and assigns of the Company.

 

12.2 Amendment
and Waiver. No provision of this Agreement shall be modified, amended, waived or discharged unless the modification, amendment, waiver
or discharge is agreed to in writing, specifying such modification, amendment, waiver or discharge, and signed by the Executive and by
an authorized officer of the Company (other than the Executive). No waiver by either party of any breach of, or of compliance with, any
condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the
same condition or provision at another time.

 

    9

     

    

 

12.3 Withholding
Taxes. All payments made under this Agreement shall be subject to deduction of all federal, state, local and other taxes required
to be withheld by applicable law.

 

12.4 Severability.
The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of
any other provision hereof, which shall remain in full force and effect.

 

12.5 Choice
of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of
Texas, without regard to where the Executive has their residence or principal office or where they perform their duties hereunder.

 

12.6 No
Duty to Mitigate. The Executive is not required to seek alternative employment following termination, and payments called for under
this Agreement will not be reduced by earnings from any other source.

 

12.7. Section
409A of the Code. The intent of the parties is that payments and benefits under this Agreement comply with Section 409A of the Code
and the Treasury Regulations and guidance promulgated thereunder (“Section 409A”), to the extent subject thereto, and
accordingly, to the maximum extent permitted, this letter shall be interpreted and administered to be in compliance therewith. Notwithstanding
anything contained herein to the contrary, Executive shall not be considered to have terminated employment with the Company for purposes
of any provision in this Agreement providing for the payment of any amounts or benefits subject to Section 409A upon or following a termination
of employment until Executive would be considered to have incurred a “separation from service” from the Company within the
meaning of Section 409A and this Agreement shall be interpreted consistently therewith. Without limiting the foregoing, and notwithstanding
anything to the contrary contained herein, to the extent (a) any payments or benefits to which Executive becomes entitled under this Agreement,
or under any agreement or plan referenced herein, in connection with Executive’s termination of employment with the Company constitute
deferred compensation subject to Section 409A of the Code and (b) Executive is deemed at the time of such termination of employment to
be a “specified employee” under Section 409A of the Code, then such payments shall not be made or commence until the earliest
of (i) the expiration of the six (6)-month period measured from the date of Executive’s “separation from service” (as
such term is at the time defined in Treasury Regulations under Section 409A of the Code) from the Company; or (ii) the date of Executive’s
death following such separation from service; provided, however, that such deferral shall only be effected to the extent required to avoid
adverse tax treatment to Executive, including (without limitation) the additional twenty percent (20%) tax for which Executive would otherwise
be liable under Section 409A(a)(1)(B) of the Code in the absence of such deferral. Upon the expiration of the applicable deferral period,
any payments which would have otherwise been made during that period (whether in a single sum or in installments) in the absence of this
paragraph shall be paid to Executive or Executive’s beneficiary in one lump sum (without interest). Any termination of Executive’s
employment is intended to constitute a “separation from service” as such term is defined in Treasury Regulation Section 1.409A-1.
It is intended that each installment of the payments provided hereunder constitute separate and distinct “payments” for purposes
of Section 1.409A of the Code. It is further intended that payments hereunder satisfy, to the greatest extent possible, the exemption
from the application of Code Section 409A (and any state law of similar effect) provided under Treasury Regulation Section 1.409A-1(b)(4)
(as a “short-term deferral”). The Company makes no representation that any or all of the payments described or referenced
in this letter will be exempt from or comply with Section 409A and makes no undertaking to preclude Section 409A from applying to any
such payment, and Company’s only obligation is to comply with its obligations set forth herein.

 

12.8 Entire
Agreement. This Agreement represents the entire agreement and understanding between the parties as to the subject matter herein (whether
oral or written and whether express or implied). The Executive hereby acknowledges, represents and warrants that they have been individually
represented by counsel in negotiating and signing this agreement.

 

[SIGNATURE
PAGE FOLLOWS]

 

    10

     

    

 

In Witness
Whereof, each of the parties has executed this Agreement, in the case of the Company, by its duly authorized officer, as of the
day and year first above written.

 

	 	Executive
	 	
	 	/s/ Hang Thi Bich Pham
	 	HANG THI BICH PHAM
	 	 	 
	 	7208 Cielo Azul Pass
	 	Austin, TX 78732

 

	 	Ipsidy Inc.
	 	 
	 	By:	/s/ Thomas L. Thimot
	 	 	Thomas L. Thimot, CEO

 

    11

     

    

 

EXHIBIT 1

 

RELEASE OF CLAIMS

 

This General Release of all
Claims (this “Release”) is entered into on [●], by and between IPSIDY INC., a Delaware corporation (the
“Company”), and HANG THI BICH PHAM (the “Executive”).

 

In accordance with Section
7.3 of the Executive Retention Agreement by and between the Company and the Executive, effective __________, 2021 (the “Retention
Agreement”), in consideration of the payments and benefits to which the Executive is entitled pursuant to the Retention Agreement
subject to the execution and non-revocation of this Release, the Executive agrees as follows:

 

		●	General Release and Waiver of Claims.

 

		○	Release. The Executive and each of the Executive’s respective heirs, executors, administrators,
representatives, agents, successors and assigns (collectively, the “Releasors”) hereby irrevocably and unconditionally
release and forever discharge the Company and each of its subsidiaries and affiliates and each of their respective officers, employees,
directors, managers, shareholders and agents (“Releasees”) from any and all claims, actions, causes of action, rights,
judgments, obligations, damages, demands, accountings or liabilities of whatever kind or character (collectively, “Claims”),
including, without limitation, any Claims under any federal, state, local or foreign law, that the Releasors may have or in the future
may possess, arising out (i) of the Executive’s employment relationship with and service as an employee, officer, manager or director
of the Company, and the termination of such relationship or service and (ii) any event, condition, circumstance or obligation that occurred,
existed or arose on or prior to the date hereof; provided, however, that notwithstanding anything else herein to the contrary,
this Release shall not affect: the obligations of the Company to pay the amounts due and owing to Executive on the Termination Date or
other obligations that, in each case, by their terms, are to be performed after the date hereof by the Company; any indemnification or
similar rights the Executive has as a current or former officer, manager or director of the Company, including, without limitation, any
and all rights thereto referenced in the Company’s governance documents or any rights with respect to “directors’ and
officers’” insurance policies; and the Executive’s right to reimbursement of business expenses.

 

		○	Specific Release of ADEA Claims. The Releasors hereby unconditionally release and forever discharge
the Releasees from any and all Claims that the Releasors may have as of the date the Executive signs this Release arising under the Federal
Age Discrimination in Employment Act of 1967, as amended, and the applicable rules and regulations promulgated thereunder (“ADEA”).
By signing this Release, the Executive hereby acknowledges and confirms the following: (i) the Executive was advised by the Company
in connection with their termination to consult with an attorney of their choice prior to signing this Release and to have such attorney
explain to the Executive the terms of this Release, including, without limitation, the terms relating to the Executive’s release
of claims arising under ADEA, and the Executive has in fact consulted with an attorney; (ii) the Executive was given a period of
not fewer than twenty-one (21) calendar days to consider the terms of this Release and to consult with an attorney of their choosing with
respect thereto; and (iii) the Executive knowingly and voluntarily accepts the terms of this Release. The Executive also understands
that they have seven (7) calendar days following the date on which they sign this Release within which to revoke the release contained
in this paragraph, by providing the Company a written notice of their revocation of the release and waiver contained in this paragraph.

 

    12

     

    

 

		○	Release of All Claims. The Executive acknowledges, understands and agrees that they may later discover
Claims or facts in addition to or different from those which they now knows or believes to be true with respect to the subject matters
of this Release, but that it is nevertheless their intention by signing this Release to fully, finally and forever release any and all
Claims whether now known or unknown, suspected or unsuspected, which now exist, may exist, or previously have existed as set forth herein.

 

		○	For California Residents - California Civil Code Section 1542 Waiver. The Executive has read the
provisions of California Civil Code Section 1542 and has consulted their own counsel regarding that section. The Executive waives any
and all rights under California Civil Code Section 1542, which states:

 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR
OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN THEIR FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY THEM, WOULD
HAVE MATERIALLY AFFECTED THEIR SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.

 

		○	Executive agrees and acknowledges that the released claims extend to and include unknown and unsuspected
claims. In furtherance of the Executive’s intent, the release in this Release shall remain in full and complete effect notwithstanding
the discovery or existence of any additional, contrary, or different facts.

 

		○	No Assignment. The Executive represents and warrants that they have not assigned any of the Claims
being released under this Release.

 

● Proceedings.
The Executive has not filed, and agrees not to initiate or cause to be initiated on their behalf, any complaint, charge, claim or
proceeding against the Releasees before any local, state or federal agency, court or other body, other than in respect of any matter
described in the proviso to Section 1(a) of this Release (each, individually, a “Proceeding”), and agrees not to
participate voluntarily in any Proceeding. The Executive waives any right they have may have to benefit in any manner from any
relief (whether monetary or otherwise) arising out of any Proceeding.

 

● Remedies.
The Executive understands that by entering into this Release they have will be limiting the availability of certain remedies that
they have may have against the Company and limiting also their ability to pursue certain claims against the Company.

 

● Severability
Clause. In the event any provision or part of this Release is found to be invalid or unenforceable, only that particular
provision or part so found, and not the entire Release, will be inoperative.

 

●
Non-admission. Nothing contained in this Release will be deemed or construed as an admission of wrongdoing or liability on the
part of the Company.

 

    13

     

    

 

● Governing
Law. All matters affecting this Release, including the validity thereof, are to be governed by, and interpreted and construed in
accordance with, the laws of the State of Texas applicable to contracts executed in and to be performed in that State.

 

● Capitalized
Terms. Capitalized terms used but not defined herein have the meanings ascribed to them in the Retention Agreement.

 

THE EXECUTIVE ACKNOWLEDGES THAT THEY HAVE READ
THIS RELEASE AND THAT THEY FULLY KNOW, UNDERSTAND AND APPRECIATE ITS CONTENTS, AND THAT THEY HEREBY EXECUTES THE SAME AND MAKES THIS AGREEMENT
AND THE RELEASE AND AGREEMENTS PROVIDED FOR HEREIN VOLUNTARILY AND OF THEIR OWN FREE WILL.

 

IN WITNESS WHEREOF, the Executive
has executed this Release on the date first set forth below.

 

	EXECUTIVE:	 
	 	 
	______________________________________	 
	HANG THI BICH PHAM	 
	 	 
	ACKNOWLEDGED AND AGREED	 

 

	IPSIDY INC.	 
	 	 	 
	By:	_________________________________	 
	Its:	_________________________________	 

 

    14

     

    

 

EXHIBIT C

 

EMPLOYEE INVENTION ASSIGNMENT AND CONFIDENTIALITY
AGREEMENT

 

THIS EMPLOYEE INVENTION ASSIGNMENT AND CONFIDENTIALITY
AGREEMENT is entered into as of the 25th day of April, 2022 between I the undersigned HANG THI BICH PHAM residing at 7208
Cielo Azul Pass Austin, TX 78732 and IPSIDY INC., a Delaware corporation with a place of business at 670 Long Beach Boulevard,
Long Beach, New York 11561 USA, (the “Company”).

 

WHEREAS, I have agreed to be an employee of the
Company or one of its affiliated entities (collectively referred to herein as the “Company”).

 

IN CONSIDERATION OF, and as a condition of my
employment with the Company (the receipt and sufficiency of which I hereby acknowledge) I hereby represent to, and agree with the Company
as follows:

 

1. Purpose
of Agreement. I understand that it is critical for the Company to preserve and protect its
rights in “Inventions” (as defined in Section 2 below), its “Confidential Information”
(as defined in Section 7 below) and in all related intellectual property rights. Accordingly, I am entering into this Employee Invention
Assignment and Confidentiality Agreement (this “Agreement”) as a condition of my employment with the Company.

 

2. Disclosure
of Inventions. I will promptly disclose in confidence to the Company all inventions, improvements,
designs, original works of authorship, formulas, processes, compositions of matter, computer software programs, databases, mask works
and trade secrets (the “Inventions”) that I make or conceive or first reduce to practice or create, either alone
or jointly with others, during the period of my employment, whether or not in the course of my employment, and whether or not such Inventions
are patentable, copyrightable or protectable as trade secrets.

 

3. Work
for Hire. I acknowledge and agree that any copyrightable works prepared by me within the
scope of my employment, including for the avoidance of doubt any such works prepared prior to the date hereof are “works made for
hire” under the Copyright Law of the United States and that the Company will be considered the author and owner of such copyrightable
works. 

 

4. Assignment
of Inventions. I agree that all Inventions that (i) have been or are developed using
equipment, supplies, facilities, Confidential Information, or trade secrets of the Company, (ii) result from work performed by me
for the Company, or (iii) relate to the Company’s business or current or anticipated research and development (the “Assigned
Inventions”), will be the sole and exclusive property of the Company and are hereby irrevocably assigned by me to the Company.

 

5. Assignment
of Other Rights; Moral Rights. In addition to the foregoing assignment of Assigned Inventions
to the Company, I hereby irrevocably transfer and assign to the Company: (i) all worldwide patents, patent applications, copyrights,
mask works, trade secrets and other intellectual property rights, including but not limited to rights in databases, in any Assigned Inventions,
along with any registrations of or applications to register such rights; and (ii) any and all “Moral Rights” (as defined
below) that I may have in or with respect to any Assigned Inventions. I also hereby forever waive and agree never to assert any and all
Moral Rights I may have in or with respect to any Assigned Inventions, even after termination of my work on behalf of the Company. “Moral
Rights” mean any rights to claim authorship of or credit on an Assigned Invention, to object to or prevent the modification
or destruction of any Assigned Inventions, or to withdraw from circulation or control the publication or distribution of any Assigned
Inventions, and any similar right, existing under judicial or statutory law of any country or subdivision thereof in the world, or under
any treaty, regardless of whether or not such right is denominated or generally referred to as a “moral right.” 

 

    -1-

     

    

 

6. Assistance.
I agree to assist the Company in every proper way, at the Company’s cost, to obtain for the Company and enforce patents, copyrights,
mask work rights, trade secret rights and other legal protections for the Company’s Assigned Inventions in any and all countries.
I will execute any documents that the Company may reasonably request for use in obtaining or enforcing such patents, copyrights, mask
work rights, trade secrets and other legal protections. My obligations under this paragraph will continue beyond the termination of my
employment with the Company, provided that the Company will compensate me at a reasonable rate after such termination for time or expenses
actually spent by me at the Company’s request on such assistance. I appoint the Secretary of the Company as my attorney-in-fact
to execute documents on my behalf for this purpose.

 

7. Confidential
Information. I understand that my employment by the Company creates a relationship of confidence
and trust with respect to any information that may be disclosed to me by the Company and its officers, employees, shareholders or agents,
whether orally, in writing, by computer or other medium, by demonstration, by supply of samples and parts or in any other manner, or which
is otherwise accessible to me, that relates to the business of the Company or to the business of any parent, subsidiary, affiliate, customer
or supplier of the Company including all information received by the Company from third parties, which is subject to an obligation of
confidentiality (the “Confidential Information”). Such Confidential Information includes, but is not limited
to, Assigned Inventions, computer programming and software, Company products and services, systems, functionality, designs, hardware,
parts, concepts, specifications, features, techniques, plans, marketing, sales, performance, cost, pricing, supplier and customer information,
data, tables, schedules, contracts and other information concerning the Company and its customers. I hereby acknowledge that all such
Confidential Information belongs to the Company (or the respective customer, supplier or third party, which suppli

 

8. Confidentiality.
At all times, both during my employment and after its termination (without limitation in point of time), I will keep and hold all such
Confidential Information in strict confidence and trust. I will not use or disclose any Confidential Information without the prior written
consent of the Company, except as may be necessary to perform my duties as an employee of the Company for the benefit of the Company.
Upon termination of my employment with the Company, I will promptly deliver to the Company all documents and materials of any nature pertaining
to my work with the Company. I will not take with me or retain any documents or materials or copies thereof containing any Confidential
Information. I agree that I shall at all times comply with the Company’s Information Security Policy and Procedures from time to
time in force. I acknowledge that breach of this policy or any other provision of this Agreement may be grounds for immediate dismissal.

 

9. No
Breach of Agreement or Infringement. I represent that my acceptance of the Company’s
offer of employment, performance of all the terms of this Agreement and my duties as an employee of the Company will not so far as I am
aware breach any invention assignment, proprietary information, confidentiality or similar agreement with any other party, nor infringe
the rights of any third party. I represent that I will not bring with me to the Company or use in the performance of my duties for the
Company any documents or materials or intangibles of a former employer or third party that are not generally available to the public or
have not been legally transferred to the Company. I acknowledge that the Company is relying upon my warranty, representation and acknowledgement
in this paragraph in offering me employment. 

 

10. Notification.
I hereby authorize the Company to notify my actual or future employers of the terms of this Agreement and my responsibilities hereunder.

 

11. Injunctive
Relief. I understand that in the event of a breach or threatened breach of this Agreement
by me the Company may suffer irreparable harm and will therefore be entitled to injunctive relief to enforce this Agreement.

 

12. Governing
Law; Jurisdiction. This Agreement will be governed by and construed in accordance with the
laws of the State of New York, without giving effect to that body of laws pertaining to conflict of laws. I hereby submit to the jurisdiction
of and consent to suit in the courts, Federal and State located in the State of New York with respect to any matter or dispute arising
out of this Agreement.

 

    -2-

     

    

 

13. Severability.
If any provision of this Agreement is determined by any court or arbitrator of competent jurisdiction
to be invalid, illegal or unenforceable in any respect, such provision will be enforced to the maximum extent possible given the intent
of the parties hereto. If such clause or provision cannot be so enforced, such provision shall be stricken from this Agreement and the
remainder of this Agreement shall be enforced as if such invalid, illegal or unenforceable clause or provision had (to the extent not
enforceable) never been contained in this Agreement.

 

14. Counterparts.
This Agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original,
and all of which together shall constitute one and the same agreement.

 

15. Entire
Agreement. This Agreement and the documents referred to herein constitute the entire agreement
and understanding of the parties with respect to the subject matter of this Agreement, and supersede all prior understandings and agreements,
whether oral or written, between or among the parties hereto with respect to the specific subject matter hereof.

 

16. Amendment
and Waivers. This Agreement may be amended only by a written agreement executed by each of
the parties hereto. No amendment of or waiver of, or modification of any obligation under this Agreement will be enforceable unless set
forth in a writing signed by the party against which enforcement is sought. Any amendment effected in accordance with this section will
be binding upon all parties hereto and each of their respective successors and assigns. No delay or failure to require performance of
any provision of this Agreement shall constitute a waiver of that provision as to that or any other instance. No waiver granted under
this Agreement as to any one provision herein shall constitute a subsequent waiver of such provision or of any other provision herein,
nor shall it constitute the waiver of any performance other than the actual performance specifically waived.

 

17. Successors
and Assigns; Assignment. Except as otherwise provided in this Agreement, this Agreement,
and the rights and obligations of the parties hereunder, will be binding upon and inure to the benefit of their respective successors,
assigns, heirs, executors, administrators and legal representatives. The Company may assign any of its rights and obligations under this
Agreement to any entity which is my employer. No other party to this Agreement may assign, whether voluntarily or by operation of law,
any of its rights and obligations under this Agreement, except with the prior written consent of the Company.

 

18. Further
Assurances. The parties agree to execute such further documents and instruments and to take
such further actions as may be reasonably necessary to carry out the purposes and intent of this Agreement.

 

SIGNED AS OF THIS 25th_ DAY OF APRIL 2022

 

	HANG THI BICH PHAM	 
	 	 
	/s/ Hang Thi Bich Pham	 

 

 

-3-Exhibit
4.1

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED
UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, (II) SUCH SECURITIES MAY
BE SOLD PURSUANT TO RULE 144, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER
MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED INVESTOR”
AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT

 

VNUE,
INC.

 

	Warrant Shares: 57,777,778	Issue
                      Date: April 19, 2022

 

THIS
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, GHS Investments, LLC or its assigns
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the Issue Date to subscribe for and purchase from VNUE, Inc., a Nevada corporation (the “Company”),
up to 57,777,778 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. This Warrant shall
expire on the five (5) year anniversary of the Issue Date. The purchase price of one share of Common Stock under this Warrant shall be
equal to the Exercise Price, as defined in Section 2(b).

 

Section 1.
Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities
Purchase Agreement (the “Purchase Agreement”), dated April 19, 2022, among the Company and the purchasers signatory
thereto.

 

     

     

    

 

Section 2. Exercise.

 

a) Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Issue Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing
to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile copy (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto. Within two (2) Trading Days following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer
or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is
specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant
Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the
Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the
effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face hereof.

 

b) Exercise
Price. The exercise price per share of the Common Stock under this Warrant shall be $0.00594, subject to adjustment hereunder (the
“Exercise Price”).

 

c) Cashless
Exercise. If at any time there is no effective registration statement registering, or no current prospectus available for, the resale
of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at any time by means of a “cashless
exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing
[(A-B) (X)] by (A), where:

 

		(A)	= 	the VWAP (as defined below) immediately preceding the time
of delivery of the Notice of Exercise giving rise to the applicable “cashless exercise”, as set forth in the applicable Notice
of Exercise (to clarify, the “last VWAP” will be the last VWAP as calculated over an entire Trading Day such that, in the
event that this Warrant is exercised at a time that the Trading Market is open, the prior Trading Day’s VWAP shall be used in this
calculation);

 

		(B)	= 	the Exercise Price of this Warrant, as adjusted hereunder;
and

 

		(X)	= 	the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise.

 

    2

     

    

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of
the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary
to this Section 2(c).

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets”
published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most
recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock
as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

d) Mechanics
of Exercise.

 

i. Delivery
of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted by the Transfer Agent to the Holder by crediting
the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective
registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant
Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by
physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the
number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice
of Exercise by the date that is one (1) Trading Day after the delivery to the Company of the Notice of Exercise (such date, the “Warrant
Share Delivery Date”). Upon delivery of the Notice of Exercise the Holder shall be deemed for all corporate
purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
of the date of delivery of the Warrant Shares; provided payment of the aggregate Exercise Price (other than in the case of a Cashless
Exercise) is received within three Trading Days of delivery of the Notice of Exercise. If the Company fails for any reason to deliver
to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder,
in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of
the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth
Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant
Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST
program so long as this Warrant remains outstanding and exercisable.

 

    3

     

    

 

ii. Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.

 

iii. Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv. Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i)
above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker
to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a
“Buy-In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.

 

    4

     

    

 

v. No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.

 

vi. Charges,
Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.

 

vii. Closing
of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.

 

    5

     

    

 

e) Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates,
and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such Persons,
“Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged
by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of
the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of
whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and
Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the
submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this Warrant is exercisable (in
relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this
Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to
verify or confirm the accuracy of such determination. In addition, a determination as to any group status as
contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or
annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more
recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the
written or oral request of a Holder, the Company shall within three Trading Days confirm orally and in writing to the Holder the
number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its
Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
“Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon
notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the
provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be
effective until the 61st day after such written notice is delivered to the Company. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to
correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The
limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

    6

     

    

 

Section 3. Certain
Adjustments.

 

a) Stock
Dividends, Splits and Reclassifications. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend
or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by
a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately
before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event,
and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price
of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after
the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.

 

b) Subsequent
Equity Sales. If the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is outstanding, shall sell
or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale,
grant or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less
than the Exercise Price then in effect (such lower price, the “Base Share Price” and such issuances collectively,
a “Dilutive Issuance”) (it being understood and agreed that if the holder of the Common Stock or Common Stock Equivalents
so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange
prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to
receive shares of Common Stock at an effective price per share that is less than the Exercise Price, such issuance shall be deemed to
have occurred for less than the Exercise Price on such date of the Dilutive Issuance at such effective price), then simultaneously with
the consummation (or, if earlier, the announcement) of each Dilutive Issuance the Exercise Price then in effect shall be reduced and
only reduced to an amount equal to the Base Share Price and the number of Warrant Shares issuable hereunder shall be increased such that
the aggregate Exercise Price payable hereunder, after taking into account the decrease in the Exercise Price, shall be equal to the aggregate
Exercise Price prior to such adjustment. The Company shall notify the Holder, in writing, no later than the Trading Day following the
issuance or deemed issuance of any Common Stock or Common Stock Equivalents subject to this Section 3(b), indicating therein the
applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the “Dilutive
Issuance Notice”). For purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice pursuant to
this Section 3(b), upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of Warrant Shares based
upon the Base Share Price regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise. If the
Company enters into a variable rate transaction, the Company shall be deemed to have issued Common Stock or Common Stock Equivalents
at the lowest possible conversion or exercise price at which such securities may be converted or exercised.

 

    7

     

    

 

c) Subsequent
Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or
sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to all record holders
of any class of shares of Common Stock (the “Purchase Rights”), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the
Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

d) Pro
Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided,
however, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation).

 

    8

     

    

 

e) Fundamental
Transaction.

 

(1)
If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease,
license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related
transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person)
is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash
or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other
than as a result of a stock split, combination or reclassification of shares of Common Stock covered by Section 3(a) above), or
(v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another
Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including
any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons
making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor
or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate
Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock
for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e)
on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at
the Holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction,
purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised
portion of this Warrant on the date of the consummation of such Fundamental Transaction. “Black Scholes Value” means
the value of this Warrant based on the Black and Scholes Option Pricing Model obtained from the “OV” function on Bloomberg,
L.P. (“Bloomberg”) determined as of the day of consummation of the applicable Fundamental Transaction for pricing
purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a five-year period, (B) an expected
volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day
immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such
calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any,
being offered in such Fundamental Transaction and (D) a remaining option time equal to five years from the date of the public announcement
of the applicable Fundamental Transaction. The payment of the Black Scholes Value will be made by wire transfer of immediately available
funds within five Business Days of the Holder’s election (or, if later, on the effective date of the Fundamental Transaction).
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor
Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents
in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option
of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock
of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares
of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital
stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such
Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall
refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named
as the Company herein.

 

    9

     

    

 

f) Calculations.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be
the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g) Notice
to Holder.

 

i. Adjustment
to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

 

ii. Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email
address as it shall appear upon the Warrant Register of the Company, at least ten (10) calendar days prior to the applicable record or
effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date
as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the
period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly
set forth herein.

 

Section 4. Transfer
of Warrant.

 

a) Transferability.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions
of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as
applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new
Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The Holder shall be required
to physically surrender this Warrant to the Company within three (3) Trading Days of the date the Holder delivers an assignment form
to the Company assigning this Warrant full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder
for the purchase of Warrant Shares without having a new Warrant issued.

 

    10

     

    

 

b) New
Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c) Warrant
Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.

 

d) Transfer
Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee
of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.

 

e) Representation
by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.

 

Section 5. Miscellaneous.

 

a) No
Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.

 

b) Loss,
Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.

 

    11

     

    

 

c) Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day.

 

d) Authorized
Shares.

 

The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

    12

     

    

 

Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.

 

e) Jurisdiction.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.

 

f) Restrictions.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.

 

g) Nonwaiver
and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. If the Company willfully and knowingly fails
to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder
such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.

 

h) Notices.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.

 

i) Limitation
of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.

 

j) Remedies.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.

 

k) Successors
and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.

 

    13

     

    

 

l) Amendment.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

 

m) Severability.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

 

n) Headings.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.

 

********************

 

(Signature
Page Follows)

 

    14

     

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	 	VNUE, INC.
	 	 	 
	 	By:	 
	 		Name:	Zach Bair
	 		Title:	CEO

 

    15

     

    

 

NOTICE
OF EXERCISE

 

		To:	VNUE,
INC.

 

(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

 

(2) Payment
shall take the form of (check applicable box):

 

☐ in lawful money of the United States; or

 

☐ if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).

 

(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

	 		 

 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number:

 

	 		 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

 

(4)
Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

	Name of Investing Entity:	 	 
	Signature of Authorized Signatory of Investing Entity:	 	 
	Name of Authorized Signatory:	 	 
	Title of Authorized Signatory:	 	 
	Date:	 	 

 

    16

     

    

 

 EXHIBIT
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

	Name:	 
	 	(Please Print)
	 	 
	Address:	 
	 	(Please Print)
	 	 
	Phone Number:	 
	 	 
	Email Address:	

 

	Dated: _______________
    __, ______
	 
	Holder’s Signature:	 	 
	 	 	 
	Holder’s Address: 	 	 

 

    B-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]